Status:
RECRUITING
TSH Suppression During Radiotherapy on Thyroid Site to Prevent Iatrogenic Hypothyroidism in Pediatric Cancer Patients
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Conditions:
Hypothyroidism; Irradiation
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
To offer the possibility of a treatment that could achieve a meaningful reduction in the incidence of post-radiation therapy hypothyroidism. Thyroid dysfunction may develop from a few months to severa...
Detailed Description
Patients will undergo basal thyroid ultrasound and FT3, FT4, TSH assay. Simulations with computed tomography, and computer assisted three-dimensional treatment planning with a dose volume histogram wi...
Eligibility Criteria
Inclusion
- Any patient with medulloblastoma, Hodgkin/non-Hodgkin Lymphoma before radiotherapy (RT) planning including thyroid parenchyma without previous primary or secondary hypothyroidism;
- Written informed consent prior to any study-specific analysis and/or data collection.
Exclusion
- Any patient with medulloblastoma, Hodgkin/non-Hodgkin Lymphoma after radiotherapy including thyroid parenchyma;
- Not signed consent.
Key Trial Info
Start Date :
December 13 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2029
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT05316922
Start Date
December 13 2021
End Date
September 30 2029
Last Update
December 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy, 20133